A strategic alliance between Rephine  (https://www.rephine.com) and

ValGenesis (https://www.valgenesis.com) will give pharmaceutical companies digital

end-to-end compliance solutions to enhance quality assurance across their entire global

supply chains.

Under the new partnership, Rephine will implement and manage next-generation digital validation and manufacturing intelligence software tools developed by ValGenesis to enhance QA.  

“ValGenesis and Rephine are collaborating to help life sciences companies enforce standardization and consistency in validation across their supply chains.  Our joint solutions will help these organizations meet their compliance obligations, reduce risks, increase efficiency, and lower the cost of ensuring quality,” says Bo Olsen, Senior Vice President of Partners, ValGenesis.  “This powerful partnership, which leverages the strengths of both our companies, creates compelling value for customers.”

“At Rephine we are accelerating the growth of our international consulting services, focusing on our deep expertise in the digitalization of QA and compliance.  This strategic partnership with ValGenesis, the global leader in VLMS, is the ideal combination of expertise and technology to deliver optimum solutions that address our clients’ business challenges,” adds Adam Sherlock, CEO, Rephine.

“The state-of-the-art design of ValGenesis’s solutions, combined with Rephine’s deep experience in validation and qualification processes, unlock the door of validation best practices for customers while also enhancing their internal processes.”

Rephine has comprehensively supported the pharmaceutical, biotech, and medical device industry for more than 25 years in its validation/qualification needs and is recognized as the gold standard in its field.